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In the United Kingdom, the National Screening Pro-
gramme for identiﬁ  cation of hepatitits B virus (HBV) infec-
tion in pregnant women uses HBV e antigen (HBeAg) and 
antibody to HBeAg (anti-HBe) as markers of infectivity to 
determine use of immunoglobulin for hepatitis B. Serum 
samples from 114 HBV-infected women were analyzed. 
Viral loads correlated with HBeAg/anti-HBe status and vi-
ral genotypes. Among 95 mothers whose serum contained 
anti-HBe, viral loads ranged between undetectable and 
8.6 × 106 IU/mL (median 228 IU/mL). Ten (10.5%) of these 
mothers had plasma viral loads >104 IU/mL; 6 were infected 
with genotype E and one each with genotypes A, B, C, and 
D. All viruses had precore stop codon or basal core pro-
moter mutations. Preponderance of genotypes other than 
A among antenatal mothers in the United Kingdom reﬂ  ects 
increasing globalization and trends in immigration. HBeAg 
serostatus is no longer sufﬁ  ciently accurate for inferring po-
tential infectivity of pregnant HBV carriers.
H
epatitis B virus (HBV) infection remains a major 
health problem worldwide and mother-to-infant trans-
mission represents one of the most efﬁ  cient ways of main-
taining hepatitis B carriage in any population. Intervention 
to prevent this route of infection is a key part of the global 
program of hepatitis B control. Although there are 3 routes 
of transmission of HBV from infected mothers to their in-
fants, including transplacental and postnatal, most transmis-
sion is likely to occur perinatally at the time of labor and 
delivery (1). HBV e antigen (HBeAg) in maternal serum is 
associated with high infectivity; in the absence of interven-
tion after delivery, including both passive and active im-
munization, 90% of babies born to carrier mothers whose 
serum contains HBeAg will become chronically infected 
with HBV (2,3). Babies born to mothers whose serum con-
tains antibody to HBeAg (anti-HBe) become infected far 
less frequently (4). However, babies who are infected may 
be at risk of developing fulminant hepatitis B (2).
The prevalence of HBV infection in the United King-
dom is low (0.4%) (5). In the late 1990s, the World Health 
Organization (WHO) recommended introduction of global 
universal hepatitis B immunization programs (6); by March 
2002, a total of 151 countries, including 34 in Europe, had 
introduced HBV vaccine within their national immuniza-
tion programs. However, current control of mother-to-in-
fant HBV transmission in the United Kingdom is based on 
selective hepatitis B immunization of infants at risk. A re-
cent WHO survey in Europe indicated that 8 other countries 
also used this approach (7). This requires routine antenatal 
screening for HBV infection (8,9), offered by 34 countries 
in Europe, with infants born to all hepatitis B–infected 
mothers being offered immediate postnatal active immu-
nization with hepatitis B vaccine. In the United Kingdom, 
babies at highest risk for infection, those born to mothers 
whose serum does not contain anti-HBe, are offered addi-
tional passive immunization prophylaxis (10) with 200 IU 
of hepatitis B immunoglobulin (HBIg) within 24 hours of 
delivery. In this protocol, detection of anti-HBe is used to 
infer low infectivity.
Despite full prophylaxis for neonates, a small propor-
tion of infants still become persistently infected (11–13) and 
are at risk of developing sequelae of chronic HBV infection 
and increasing the HBV reservoir. Although the causes for 
these failures could be many, we noted that in management 
of HBV–infected healthcare workers, inference of infectiv-
ity is now based upon plasma viral load for HBV rather 
than HBe markers. Until 2001 in the United Kingdom, ﬁ  t-
ness of an HBV-infected healthcare worker to undertake in-
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vasive procedures was predicated upon absence of HBeAg, 
a protocol that was found to enable transmission to patients 
(14). All transmission involved infections by viruses with 
the pre-core premature stop codons, which reﬂ  ected chang-
es in viral genotypes caused by increased migration in UK 
healthcare workers. To investigate potential inappropriate 
categorization of infection risk through continued use of 
HBe markers in the antenatal setting, we undertook a study 
to relate HBe markers to HBV DNA levels and genotypes 
as predictors of potential infectivity.
Patients and Methods
Patients
As part of routine antenatal care, screening for HBV 
infection is offered to all pregnant mothers at the Uni-
versity College London Hospital. Pregnant HBV carriers 
who came to the hospital from September 1989 through 
September 2004 were identiﬁ  ed. Serum samples from 114 
HBV-infected mothers were available for further testing. 
Ethnic origin of mothers was not recorded.
Serologic Tests
Serum was separated and stored at –20°C in the De-
partment of Virology, University College London Hospi-
tal, in accordance with laboratory policy to archive samples 
from carriers because of the long incubation time to clinical 
expression of HBV-related chronic liver disease. Samples 
would have been tested at initial collection for HBsAg by 
using a range of commercial assays and had reactivity con-
ﬁ  rmed by neutralization tests. Further testing for HBeAg, 
anti-HBe, antibody to hepatitis B virus core antigen (anti-
HBc), and immunoglobulin M to HBc would have been 
performed routinely to determine the need for HBIg and 
conﬁ  rm carrier status.
Quantitative PCR and Sequencing
Viral load for HBV DNA was measured as described 
(15). Brieﬂ  y, HBV DNA was extracted from serum by using 
the QIAamp Virus BioRobot 9604 and QIAamp96 Virus 
Kit reagents (QIAGEN, Hilden, Germany) in accordance 
with the manufacturer’s instructions. Twenty microliters of 
extract was used for input into a Taqman-based assay for 
HBV DNA in an ABI Prism 7000 sequence detection sys-
tem (Applied Biosystems, Foster City, CA, USA). Serum 
samples containing >100 IU/mL of viral DNA were select-
ed for sequencing. Five microliters of extract was used for 
nested ampliﬁ  cation of the entire virus surface antigen gene 
as described (16). We ampliﬁ  ed precore and basal core pro-
moter (BCP) regions of HBV DNA from anti-HBe–posi-
tive serum samples that contained >104 IU/mL of HBV 
DNA. Brieﬂ  y, 5 μL of extracted HBV DNA was ampliﬁ  ed 
by using primers H4072, 5′-TCTTGCCCAAGGTCTTA
CAT-3′, and C outer (outer antisense), 5′-TCCCACCTTAT
GAGTCCAAG-3′, in the ﬁ  rst round and primers H4072 
(primer sequence as above) and C inner, 5′-CAGCGAG-
GCGAGGGAGTTCTTCTT-3′, in the second round. Con-
ditions for ampliﬁ  cation were the same for both rounds: 
94°C for 4 min; 35 cycles at 94°C for 30 s, 55°C for 30 
s, and 72°C for 1 min; and a ﬁ  nal extension at 72°C for 5 
min. Amplicons were sequenced with CEQ 8000 Genetic 
Analysis Systems (Beckman Coulter, Fullerton, CA, USA) 
in accordance with the manufacturer’s instructions. 
Generated nucleotide sequences were assembled and 
analyzed by using the SeqMan program (DNASTAR Inc., 
Madison, WI, USA). Alignments of nucleotide sequences 
were conducted to determine phylogenetic relationships 
between different isolates of HBV by using the MegAlign 
program (DNASTAR, Inc.). Data were used to construct 
a phylogenetic tree. Further analysis was also conducted 
with HBV STAR analysis, which assigns HBV genotypes 
by using a position-speciﬁ  c scoring matrix (www.vgb.ucl.
ac.uk/star.shtml). Statistical signiﬁ  cance was determined 
by using the Fisher exact test in the Arcus Quickstat pack-
age (www.camcode.com/arcus.htm).
Results
Thirteen (11.4%) of 114 HBsAg-positive serum sam-
ples contained detectable HBeAg, 95 (83.3%) contained 
anti-HBe, and 6 (5.3%) did not contain HBeAg or anti-
HBe. HBIg had been recommended only for babies born to 
13 mothers whose serum contained HBeAg and to 6 moth-
ers whose serum did not contain HBeAg or anti-HBe.
HBV DNA, HBeAg, Anti-HBe, and Genotypes
HBV DNA was detected in 96 (84%) serum samples 
(Figure). The 13 HBeAg-positive serum samples had viral 
loads that ranged from 7.8 × 105 to 1 × 108 IU/mL (me-
dian 2.2 × 107 IU/mL). In 95 samples positive for anti-HBe, 
viral loads ranged from undetectable to 8.6 × 106 IU/mL 
(median 228 IU/mL). In 6 serum samples with neither e 
markers detected, viral loads ranged from undetectable to 
750 IU/mL (median 120 IU/mL). Ten (10.5%) of 95 anti-
HBe–positive samples had viral loads >104 IU/mL, ranging 
up to 8.6 × 106 IU/mL.
HBV DNA extracts from 40 serum samples were suc-
cessfully sequenced and genotyped. Genotypes E (13/40, 
32.5%) and B (10/40, 25%) predominated. Genotypes A 
(6/40, 15%), C (9/40, 22.5%), and D (2/40, 5%) accounted 
for the remaining genotypes. In 10 serum samples with 
viral loads >104 IU/mL and anti-HBe, the distribution of 
genotypes was signiﬁ  cantly different, with an excess of 
genotype E (p = 0.05 by Fisher exact test; Table). Of the 10 
viruses infecting these mothers, 5 had precore changes, 3 
had precore and BCP changes, and 2 had BCP changes.
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Discussion
This study investigated the continuing use in the Unit-
ed Kingdom of maternal HBeAg markers as predicators for 
enhanced neonatal HBIg prophylaxis in addition to neo-
natal vaccine. Among 51 countries in Europe, the United 
Kingdom, along with 14 others, has elected to not intro-
duce routine neonatal HBV immunization at this time (7), 
rather opting for selective screening in the antenatal clinics 
and targeted prophylaxis to infants born to infected moth-
ers. This policy requires efﬁ  cient HBV screening in clin-
ics. We recognize that resources required for implementing 
this policy are not available in many countries. This policy 
has the advantage of enabling the addition of HBIg to pro-
phylaxis for infants born to mothers with high infectivity, 
although how widespread this practice is in Europe is not 
known. HBIg is a costly intervention and is limited by 
availability. It is also a blood product that has the risk for 
transmission of prion disease through inclusion of dona-
tions from persons with variant Creutzfeldt-Jakob disease 
in the plasma pool.
Serum samples from 114 hepatitis B carrier mothers 
were examined. Thirteen (11.4%) contained HBeAg, with 
concentrations of HBV DNA ranging from 7.8 × 105 to 1 
× 108 IU/mL. All infants born to these mothers would have 
been at high risk of acquiring HBV and should have been 
offered active immunization with the HBV vaccine, as well 
as passive prophylaxis with HBIg. Six serum samples did 
not contain detectable HBeAg or anti-HBe. Although HBV 
DNA levels were low in all samples, infants of these moth-
ers would still have been given HBIg in accordance with 
guidelines, probably unnecessarily. Eighty-ﬁ  ve of 95 se-
rum samples with anti-HBe had HBV DNA levels <104 IU/
mL and infants of these mothers would have received only 
active immunization. Ten (10.5%) of 95 serum samples 
had HBV DNA concentrations >104 IU/mL, and 2 (2.1%) 
of these had high viral loads >105 IU/mL (110,000 IU/mL 
and 8,690,000 IU/mL, respectively). The infants of these 
mothers would not have been offered HBIg on the basis 
of maternal anti-HBe as a marker of low infectivity. It is 
not known whether such infants are more likely to become 
infected as they had received only vaccine prophylaxis.
In the late 1970s in Japan, use of anti-HBe as a marker 
for low infectivity had been based on the observation (17) 
that anti-HBe–seropositive carriers were unlikely to trans-
mit hepatitis B sexually or to their infants. This belief was 
veriﬁ  ed by observations in genitourinary medicine clinics 
(18) and included in Department of Health policy in the 
United Kingdom that allowed hepatitis B carriers to con-
duct exposure-prone procedures if their serum did not con-
tain HBeAg. In retrospect, it seems likely that at the time 
of promulgation of these guidelines, most infections with 
hepatitis B virus in the UK workforce would have been 
with genotype A. This Department of Health policy contin-
ued until description of several surgical transmissions from 
HBV-infected healthcare workers (14) and the recognition 
that some carriers whose serum contained anti-HBe had 
high viral loads. After this episode, estimation of plasma 
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Figure. Box and whisker plots of hepatitis B virus (HBV) load in 
3 groups of mothers whose serum contained hepatitis B virus e 
antigen (HBeAg), antibody to hepatitis B virus e antigen (anti-
HBe), or neither of these markers (e Neg). Boxes are middle 
quartiles, horizontal lines are medians, whiskers are ranges, and 
dots represent 10 anti-HBe–seropositive mothers whose serum 
contained >104 IU/mL HBV DNA. Thirty-three anti-HBe–seropositive 
mothers and 1 mother whose serum did not contain either marker 
did not have detectable HBV DNA (<50 IU/mL).
Table. Characteristics of HBV in 10 infected mothers seropositive 









1 D 2.5 × 10
4 WW 2 8
2 E 1 × 10
4 WW 2 8
3 E 1.1 × 10
4 130K/131I W28
G29D
4 C 1.1 × 10
5 130K/131I W
5 B 1.7 × 10
4 130K/131I W28
6 E 8.6 × 10
6 WW 2 8
7 A 3.4 × 10
4 130K/131I W
8 E 1.9 × 10
4 WW 2 8
9 E 2.2 × 10
4 130K/131I W28
10 E 1.0 × 10
4 WW 2 8
*HBV, hepatitis B virus; W, wild-type sequence. 
†W28, premature stop at codon 28. RESEARCH
HBV DNA load was introduced to manage infected health-
care workers (19). Most of the surgeons involved had been 
born in HBV-endemic countries outside Europe and would 
have been infected by a genotype other than genotype A. 
All viruses transmitted had premature stop codons in the 
precore region, which are changes not commonly seen in 
genotype A infections.
Dominance of nongenotype A infections among ante-
natal women in the United Kingdom, with genotype A ac-
counting for only 15%, is explained by the recent observa-
tion that a net of ≈6,000 HBV carriers immigrate annually to 
the United Kingdom (5) from areas such as eastern Europe, 
where non-A viruses predominate. This immigration will un-
doubtedly change clinical expression of HBV carriage in the 
United Kingdom and provides an example of reemergence 
of an old virus disease with different characteristics. Flaring 
(increase in alanine aminotransferase levels caused by im-
mune-mediated destruction of hepatocytes) and late escape 
(elevated levels of viral DNA) of virus from host-dependent 
modulation (innate or adaptive immune responses to infec-
tion with HBV) is seen more frequently with non-A viruses 
than with European genotype A HBV. All but 1 of the vi-
ruses in serum samples from 10 anti-HBe carrier mothers 
who had high viral loads were non-A, and all carried changes 
associated with enhanced virus replication. Five had changes 
in the precore region, 2 had changes in the BCP, and 3 had 
changes in both regions.
BCP mutations at nucleotide positions 1762/1764 and 
precore mutation G1896A, which results in a premature 
stop at codon 28, reduce or prevent expression of HBeAg. 
Both mutations are likely the result of virus evolution and 
selection of the ﬁ  ttest strains (20) during host immune re-
sponses. BCP changes result in decreased transcription of 
precore/core mRNA, reduced secretion of HBeAg (21), and 
enhanced virus production in vitro (22,23). These changes 
have been detected more often in viruses with genotypes A 
and C than in those with genotypes B, D, and E (24). How-
ever, in our study, BCP mutations were seen in viruses with 
genotypes A, C, D, and E. These mutations are thought to 
arise before precore changes (25). The premature stop pre-
core mutation is restricted to HBV genotypes containing a 
thymidine at nucleotide position 1858, which is required 
for stabilizing the stem loop structure (26). This mutation, 
which is found in viruses with genotypes B, D, E, G and 
some strains with genotypes C and A (27), explains the high 
prevalence of premature stop variants in Asia and the Medi-
terranean region, where predominant genotypes are B, C, 
and D and their previous low prevalence in the United King-
dom. Our study demonstrates changing phenotypes of virus 
infections caused by population movement. These changes 
are unlikely to be limited to the United Kingdom and have 
wider implications for infectious diseases globally.
Our study demonstrates that reliance on only HBV se-
rologic markers leads to misclassiﬁ  cation of HBV carrier 
mothers. A proportion of low-infectivity carriers had high 
levels of virus in plasma but their infants would not have re-
ceived optimal enhanced prophylaxis with postnatal HBIg. 
This policy could allow avoidable breakthrough infections 
in infants. In view of the inﬂ  ux of immigrant HBV carriers 
into the United Kingdom, a new HBV antenatal screening 
strategy is needed to identify and offer adequate protection 
to infants at risk of acquiring HBV infection. Quantiﬁ  ca-
tion of HBV DNA is a more objective direct measure of 
potential infectivity and brings this procedure in line with 
management of HBV-infected healthcare workers (19). 
However, the cut-off level of HBV DNA needed to deﬁ  ne 
potential activity has yet to be established. Finally, given 
the emerging pattern of an overall increase in HBV carriage 
in the United Kingdom, consideration should once again be 
given to a national program of immunization of infants.
Dr Dervisevic is a clinical virologist at the University Col-
lege London Hospitals, of London. His research interests include 
viral hepatitis and other bloodborne viruses.
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